<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03315949</url>
  </required_header>
  <id_info>
    <org_study_id>OC17MESI0060</org_study_id>
    <nct_id>NCT03315949</nct_id>
  </id_info>
  <brief_title>Comparison of Bowel Cleansing Efficacy Between Same-day Dose Versus Split Dose</brief_title>
  <official_title>Comparison of Bowel Cleansing Efficacy Between Same-day Dose Versus Split Dose : A Single Center, Operator Blinded, Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incheon St.Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incheon St.Mary's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Split dose bowel cleansing is recommended method for colonoscopy. For afternoon colonoscopy,&#xD;
      same-day dose of bowel cleansing is alternative option. Recently, same-day bowel cleansing&#xD;
      for morning colonoscopy was validated. To date, there was no study which compared the bowel&#xD;
      cleansing efficacy between same-day dose and split dose regardless of colonoscopy time. The&#xD;
      aim of current study is to compare the bowel cleansing efficacy, adverse events, and&#xD;
      patient's tolerability between the two group.&#xD;
&#xD;
      Subjects who underwent colonoscopy for various reasons were included. After agreeing to&#xD;
      participate in the study, study participants were randomly assigned to split dose or same day&#xD;
      dose group. Bowel cleansing is done using polyethylene glycol (PEG). All colonoscopy was done&#xD;
      between 10 AM to 6 PM. Study participants were instructed to ingest 500ml PEG every 15&#xD;
      minutes. Subjects who were assigned to split dose group ingested 2L PEG from 9PM 1 day before&#xD;
      colonoscopy. Remaining 2L PEG was ingested 3-5 hours before colonoscopy. In the same-day dose&#xD;
      group, bowel cleansing was started from 5AM for subjects who were scheduled to receive&#xD;
      colonoscopy in the morning. Afternoon colonoscopy group in the same-day dose group ingested&#xD;
      2L PEG from 5AM. Remaining 2L PEG was finished 3-5 hours before colonoscopy.&#xD;
&#xD;
      Bowel cleansing efficacy was assessed using Boston bowel preparation scale. Vital signs and&#xD;
      laboratory tests were checked before colonoscopy. Study participants completed questionnaire&#xD;
      which contained patient's satisfaction, tolerability, and adverse event during bowel&#xD;
      cleansing. Bowel cleansing efficacy, patient's tolerability, and safety profile were compared&#xD;
      between the two groups. Successful bowel cleansing was estimated 85% for split dose group.&#xD;
&#xD;
      The investigators set 10% for inferior margin. Considering 10% drop out, a total of 352&#xD;
      subjects will be recruited.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomization and blinding:&#xD;
&#xD;
      Randomization will be done using computer generated randomization list. A specialized nurse&#xD;
      will explain the method of bowel cleansing. Investigators (endoscopists) are blinded to bowel&#xD;
      cleansing method.&#xD;
&#xD;
      Endpoint:&#xD;
&#xD;
      Primary end point is successful bowel cleansing rated by Boston bowel preparation (BBPS)&#xD;
      scale. Successful bowel cleansing is defined as all segment is 2 or 3 points. Endoscopists&#xD;
      will assess BBPS when colonoscopy withdrawal.&#xD;
&#xD;
      Secondary end point was patient's tolerability and safety profile including adverse events.&#xD;
      Patient's satisfaction to the different bowel cleansing method and adverse events (nausea,&#xD;
      vomiting, dizziness, fatigue) will be investigated by questionnaire before colonoscopy. Blood&#xD;
      test will be done before colonoscopy.&#xD;
&#xD;
      Statistical analysis:&#xD;
&#xD;
      Bowel cleansing success, patient's tolerability and safety profile will be compared between&#xD;
      the two groups. Student t test for continuous variables and the chi-square test or Fisher&#xD;
      exact test for categorical variables.&#xD;
&#xD;
      Sample size:&#xD;
&#xD;
      This study is non-inferioty study. Assuming bowel cleansing success rate 85% in the&#xD;
      split-dose group, the significant difference between the two groups were hypothesized at 10%.&#xD;
      Considering 80% power and 10% drop rate, a total of 352 participants is needed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Actual">February 28, 2018</completion_date>
  <primary_completion_date type="Actual">February 28, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Boston Bowel Preparation Scale</measure>
    <time_frame>Bowel cleansing efficacy using Boston bowel preparation scale will be assessed during colonoscopy withdrawal</time_frame>
    <description>Primary endpoint=Successful bowel cleansing (all segmental score 2 or above)&#xD;
* Boston bowel preparation scale (0-9) Sum of 3 segment of bowel. 0=inadequate&#xD;
poor&#xD;
good&#xD;
excellent</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">352</enrollment>
  <condition>Unrecognized Condition</condition>
  <arm_group>
    <arm_group_label>Same-day dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who ingest bowel cleanser on the day of colonoscopy. Participant will ingest the 4L PEG on the day of colonoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Split-dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who ingest bowel cleanser by split dose. 2L PEG will be ingested 1 day before colonoscopy. Remaining 2L bowel cleanser will be ingested on the day of colonoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyethylene Glycol (PEG)</intervention_name>
    <description>Different method for bowel cleansing using same bowel cleanser. Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy</description>
    <arm_group_label>Same-day dose group</arm_group_label>
    <arm_group_label>Split-dose group</arm_group_label>
    <other_name>colyte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all subjects who undergo colonoscopy for various reasons.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hemodynamic instability&#xD;
&#xD;
          -  ileus or bowel obstruction&#xD;
&#xD;
          -  active inflammatory bowel disease&#xD;
&#xD;
          -  advanced colon cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae-Geun Gweon, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Incheon St. Mary's Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>02143</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <results_first_submitted>July 28, 2020</results_first_submitted>
  <results_first_submitted_qc>August 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2020</results_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Incheon St.Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Tae-Geun Gweon</investigator_full_name>
    <investigator_title>Clinical associate professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 18, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT03315949/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Same-day Dose Group</title>
          <description>Participants who ingest bowel cleanser on the day of colonoscopy. Participant will ingest the 4L PEG on the day of colonoscopy.&#xD;
Polyethylene Glycol (PEG): Different method for bowel cleansing using same bowel cleanser.&#xD;
Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy</description>
        </group>
        <group group_id="P2">
          <title>Split-dose Group</title>
          <description>Participants who ingest bowel cleanser by split dose. 2L PEG will be ingested 1 day before colonoscopy. Remaining 2L bowel cleanser will be ingested on the day of colonoscopy.&#xD;
Polyethylene Glycol (PEG): Different method for bowel cleansing using same bowel cleanser.&#xD;
Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who ingested bowel cleansing agent according to protocol</population>
      <group_list>
        <group group_id="B1">
          <title>Same-day Dose Group</title>
          <description>Participants who ingest bowel cleanser on the day of colonoscopy. Participant will ingest the 4L PEG on the day of colonoscopy.&#xD;
Polyethylene Glycol (PEG): Different method for bowel cleansing using same bowel cleanser.&#xD;
Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy</description>
        </group>
        <group group_id="B2">
          <title>Split-dose Group</title>
          <description>Participants who ingest bowel cleanser by split dose. 2L PEG will be ingested 1 day before colonoscopy. Remaining 2L bowel cleanser will be ingested on the day of colonoscopy.&#xD;
Polyethylene Glycol (PEG): Different method for bowel cleansing using same bowel cleanser.&#xD;
Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="172"/>
            <count group_id="B2" value="167"/>
            <count group_id="B3" value="339"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="244"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.7" spread="8.5"/>
                    <measurement group_id="B2" value="58.4" spread="9.4"/>
                    <measurement group_id="B3" value="58.0" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="339"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Boston Bowel Preparation Scale</title>
        <description>Primary endpoint=Successful bowel cleansing (all segmental score 2 or above)&#xD;
* Boston bowel preparation scale (0-9) Sum of 3 segment of bowel. 0=inadequate&#xD;
poor&#xD;
good&#xD;
excellent</description>
        <time_frame>Bowel cleansing efficacy using Boston bowel preparation scale will be assessed during colonoscopy withdrawal</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Same-day Dose Group</title>
            <description>Participants who ingest bowel cleanser on the day of colonoscopy. Participant will ingest the 4L PEG on the day of colonoscopy.&#xD;
Polyethylene Glycol (PEG): Different method for bowel cleansing using same bowel cleanser.&#xD;
Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy</description>
          </group>
          <group group_id="O2">
            <title>Split-dose Group</title>
            <description>Participants who ingest bowel cleanser by split dose. 2L PEG will be ingested 1 day before colonoscopy. Remaining 2L bowel cleanser will be ingested on the day of colonoscopy.&#xD;
Polyethylene Glycol (PEG): Different method for bowel cleansing using same bowel cleanser.&#xD;
Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Boston Bowel Preparation Scale</title>
          <description>Primary endpoint=Successful bowel cleansing (all segmental score 2 or above)&#xD;
* Boston bowel preparation scale (0-9) Sum of 3 segment of bowel. 0=inadequate&#xD;
poor&#xD;
good&#xD;
excellent</description>
          <units>Number of successful cleansing</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected between enrollment and 4 weeks of procedure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Same-day Dose Group</title>
          <description>Participants who ingest bowel cleanser on the day of colonoscopy. Participant will ingest the 4L PEG on the day of colonoscopy.&#xD;
Polyethylene Glycol (PEG): Different method for bowel cleansing using same bowel cleanser.&#xD;
Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy</description>
        </group>
        <group group_id="E2">
          <title>Split-dose Group</title>
          <description>Participants who ingest bowel cleanser by split dose. 2L PEG will be ingested 1 day before colonoscopy. Remaining 2L bowel cleanser will be ingested on the day of colonoscopy.&#xD;
Polyethylene Glycol (PEG): Different method for bowel cleansing using same bowel cleanser.&#xD;
Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="172"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse events related to bowel cleanser</sub_title>
                <description>nausea</description>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="172"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Adverse events related to bowel cleansing agent</sub_title>
                <description>vomiting</description>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="172"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Adverse events related to bowel cleansing agent</sub_title>
                <description>bloating</description>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="172"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse events related to bowel cleansing agent</sub_title>
                <description>Headache, dizziness</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="172"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Tae-Geun Gweon</name_or_title>
      <organization>College of Medicine, The Catholic University of Korea</organization>
      <phone>82 32 340 2228</phone>
      <email>gweontae@naver.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

